Evidence map›Paper›PMID 38135919›Full record

ArticleEpilepsia open2024

Applying the ILAE diagnostic criteria for Lennox-Gastaut syndrome in the real-world setting: A multicenter retrospective cohort study.

Russell Nightscales, Zhibin Chen, Sarah Barnard, Clarissa Auvrez, Gerard Tao, Shobi Sivathamboo, Caitlin Bennett, Maria Rychkova, Wendyl D'Souza, Samuel F Berkovic and 5 more

Open access · goldAbstract readMulticenter Study
In one paragraph

Article in Epilepsia open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Observational
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Russell NightscalesDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0001-9108-207X
Zhibin ChenDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-1888-6917
Sarah BarnardDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0003-0517-2533
Clarissa AuvrezNorthWestern Mental Health, Melbourne Health, Melbourne, Victoria, Australia.
Gerard TaoDepartment of Medicine (The Royal Melbourne Hospital), The University of Melbourne, Melbourne, Victoria, Australia.
Shobi SivathambooDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0003-4638-9579
Caitlin BennettEpilepsy Research Centre, Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria, Australia.
Maria RychkovaDepartment of Medicine (The Royal Melbourne Hospital), The University of Melbourne, Melbourne, Victoria, Australia.
Wendyl D'SouzaDepartment of Medicine, St. Vincent's Hospital, The University of Melbourne, Fitzroy, Victoria, Australia.
Samuel F BerkovicEpilepsy Research Centre, Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria, Australia.ORCID https://orcid.org/0000-0003-4580-841X
John-Paul NicoloDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-0473-6475
Terence J O'BrienDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
Piero PeruccaDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0002-7855-7066
Ingrid E SchefferEpilepsy Research Centre, Department of Medicine (Austin Health), The University of Melbourne, Heidelberg, Victoria, Australia.ORCID https://orcid.org/0000-0002-2311-2174
Patrick KwanDepartment of Neuroscience, Central Clinical School, Monash University, Melbourne, Victoria, Australia.ORCID https://orcid.org/0000-0001-7310-276X
The Royal Melbourne Hospital · AUThe University of Melbourne · AUAlfred Health · AUMelbourne Health · AURoyal Children's Hospital · AU

Funding

Jazz Pharmaceuticals
6 · The paper itself

Abstract

objectiveLennox-Gastaut syndrome (LGS) is an archetypal developmental and epileptic encephalopathy, for which novel treatments are emerging. Diagnostic criteria for LGS have recently been defined by the International League Against Epilepsy (ILAE). We aimed to apply these criteria in a real-world setting.

methodsWe applied ILAE diagnostic criteria to a cohort of patients diagnosed with LGS by epileptologists following inpatient video-EEG monitoring (VEM) at tertiary comprehensive epilepsy centers between 1995 and 2015. We also assessed mortality in this cohort.

resultsSixty patients diagnosed with LGS and had complete records available for review were identified. Among them, 29 (48%) patients met ILAE diagnostic criteria for LGS (ILAE-DC group). Thirty-one did not meet criteria (non-ILAE-DC) due to the absence of documented tonic seizures (n = 7), EEG features (n = 12), or both tonic seizures and EEG features (n = 10), intellectual disability (n = 1), or drug resistance (n = 1). The ILAE-DC group had a shorter duration of epilepsy at VEM than the non-ILAE-DC group (median = 12.0 years vs. 23.7 years, respectively; p = 0.015). The proportions of patients with multiple seizure types (100% vs. 96.7%), ≤2.5 Hz slow spike-and-wave EEG activity (100% vs. 90%), seizure-related injuries (27.6% vs. 25.8%), and mortality (standardized mortality ratio 4.60 vs. 5.12) were similar between the groups. SIGNIFICANCE: Up to 52% of patients diagnosed with LGS following VEM may not meet recently accepted ILAE criteria for LGS diagnosis. This may reflect both the limitations of retrospective medical record review and a historical tendency of applying the LGS diagnosis to a broad spectrum of severe, early-onset drug-resistant epilepsies with drop attacks. The ILAE criteria allow the delineation of LGS based on distinct electroclinical features, potentiating accurate diagnosis, prognostication, and management formulation. Nonetheless, mortality outcomes between those who did and did not meet ILAE diagnostic criteria for LGS were similarly poor, and both groups suffered high rates of seizure-related injury. PLAIN LANGUAGE SUMMARY: More than half of patients diagnosed with Lennox-Gastaut Syndrome (LGS) at three Australian epilepsy monitoring units between 1995 and 2015 did not meet the recently devised International League Against Epilepsy (ILAE) diagnostic criteria for LGS. Mortality was equally high in those who did and did not meet the ILAE diagnostic criteria, and seizure-related injury was common. The ILAE diagnostic criteria will guide accurate diagnosis, management, prognostication, and research in patients with LGS, however may be limited in their practical application to patients with a longer duration of epilepsy, or to those for whom detailed assessment is difficult.

Indexed as

EpilepsyLennox Gastaut SyndromeAustraliaHumansRetrospective StudiesSeizuresdiagnosisLennox‐Gastaut syndromemulticenter studyvideo‐EEG monitoring

Identifiers

PMID38135919
PMCPMC10984283
OpenAlexW4390144115

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.